D. Liénard - Concepedia

Author

D. Liénard

University Hospital of Lausanne

Also Known As

D Lienard, D Liénard, D. LIENARD, D. LIÉNARD, D. Lienard, D. Liénard, Danièle Lienard, Daniéle Lienard, KF Koelmel

Publications

2.9K

Citations

H-Index

Concepts

All Affiliations

University Hospital of Lausanne Institut Jules Bordet Ludwig Cancer Research University of Lausanne Praxis für Hämatologie und Onkologie

About

D. Liénard is an author at University Hospital of Lausanne specializing in medicine, radiation oncology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	763
2	Health Sciences	3	3	124
3	Cell Biology	3	3	159
4	Allergy	2	2	67
5	Public Health	1	1	49

D. Liénard

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Sunscreen Use and Duration of Sun Exposure: a Double-Blind, Randomized Trial Philippe Autier, J. F. Doré, Sylvie Négrier, JNCI Journal of the National Cancer Institute	1999	239
Final results of the EORTC 18871/DKG 80-1 randomised phase III trial Ulrich R. Kleeberg, Stefan Suciu, E.‐B. Bröcker, European Journal of Cancer Clinical TrialsRandomized Controlled TrialEortc 18871/DkgDrug TrialMedicine	2003	236
Melanoma and use of sunscreens: An EORTC case‐control study in germany, belgium and france Philippe Autier, Jean‐François Doré, E. Schifflers, International Journal of Cancer	1995	225
Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: a randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group. Ulrich Keilholz, S.H. Goey, Cornelis J.A. Punt, Journal of Clinical Oncology	1997	196
Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma Pedro Romero, Nadine Gervois, J. Schneider, The Journal of Immunology	1997	169
Cutaneous malignant melanoma and exposure to sunlamps or sunbeds: An eortc multicenter case‐control study in Belgium, France and Germany Philippe Autier, Jean‐Francois Doré, Ferdy J. Lejeune, International Journal of Cancer	1994	160
Isolated limb perfusion with tumour necrosis factor-α and melphalan with or without interferon-γ; for the treatment of in-transit melanoma metastases D. Liénard, Alexander M.M. Eggermont, Heimen Schraffordt Koops, Melanoma Research	1999	148
Harly endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high‐dose tumour necrosis factor alpha (rTNFα) Nathalie Renard, D. Liénard, Laurence Lespagnard, International Journal of Cancer	1994	143
Isolated perfusion of the limb with high-dose tumour necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma) and melphalan for melanoma stage III. Results of a multi-centre pilot study. D. Liénard, Eggermont Am, Schraffordt Koops H, PubMed Isolated PerfusionMelanoma Stage IiiMedicineImmunologyIsolation Perfusion	1994	95
Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide. Mikäel J. Pittet, Daniel E. Speiser, D. Liénard, PubMed ImmunologyImmunologic MechanismAntigen ProcessingImmunotherapeuticsPeptide-based Vaccination	2001	86

Page 1